Market capitalization | $12.85b |
Enterprise Value | $20.23b |
P/E (TTM) P/E ratio | 34.08 |
EV/FCF (TTM) EV/FCF | 53.24 |
EV/Sales (TTM) EV/Sales | 2.44 |
P/S ratio (TTM) P/S ratio | 1.55 |
P/B ratio (TTM) P/B ratio | 3.94 |
Revenue growth (TTM) Revenue growth | -18.65% |
Revenue (TTM) Revenue | $8.31b |
As a Free StocksGuide user, you can view scores for all 6,845 stocks worldwide.
13 Analysts have issued a Solventum forecast:
13 Analysts have issued a Solventum forecast:
Mar '25 |
+/-
%
|
||
Revenue | 8,308 8,308 |
19%
19%
|
|
Gross Profit | 4,545 4,545 |
23%
23%
|
|
EBITDA | 1,377 1,377 |
50%
50%
|
EBIT (Operating Income) EBIT | 832 832 |
60%
60%
|
Net Profit | 379 379 |
76%
76%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Solventum Corp. operates as a health care company. The company was founded on January 24, 2023 and is headquartered in Maplewood, MN.
Head office | United States |
CEO | Bryan Hanson |
Website | www.solventum.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.